May 20, 2025
Click to open news item in new windowRafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 05, 2025
Click to open news item in new windowRafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025
Click to open news item in new windowRafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025
Click to open news item in new windowRafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025
Click to open news item in new windowRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025
Click to open news item in new windowRafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Dec 11, 2024
Click to open news item in new windowRafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 06, 2024
Click to open news item in new windowRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Aug 22, 2024
Click to open news item in new windowRafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024
Click to open news item in new windowRafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

   1    2   3   4   5   6